Omkar Speciality Chemicals Exits Insolvency, Faces Zero Revenue Challenge

Omkar Speciality Chemicals has concluded its Corporate Insolvency Resolution Process (CIRP), with the NCLT approving its resolution plan on July 31, 2025. The company has also reported financial results for the quarters ending September 2025 and December 2025, alongside significant management and board changes. The resolution plan includes a total amount of ₹26.65 crore and capital infusion of ₹9.734 crore.

Reader Takeaway: New management and CIRP exit signal a new start, but zero revenue and losses remain significant concerns.

What just happened

Omkar Speciality Chemicals Limited (OSCL) has successfully completed its Corporate Insolvency Resolution Process (CIRP). This follows the National Company Law Tribunal's (NCLT) approval of the resolution plan on July 31, 2025.

The company has released financial results for the periods ending September 30, 2025, and December 31, 2025. Key organizational shifts include the appointment of Mr. Dipak Kumar Shaw as the new Chief Executive Officer (CEO) and Mr. Ruhini Kumar Chakraborty as an Independent Director.

Additionally, M/s R.R. Tibrewala & Co. has been appointed as the new Statutory Auditors, and M/s Aabid & Co. as Secretarial Auditors for the financial year 2025-26. New Audit and Stakeholders' Relationship Committees have also been formed.

Why this matters

The conclusion of CIRP signifies a fresh start for Omkar Speciality Chemicals, moving away from its insolvency proceedings. The appointment of new leadership and auditors aims to improve governance and operational oversight.

However, the financial results present a stark picture: zero revenue from operations in both reported quarters and continued net losses. For the nine months ending December 31, 2025, the net loss stood at ₹1,25.62 lakh, and for the quarter ending September 30, 2025, it was ₹51.79 lakh.

The auditor's report highlights a 'material uncertainty' regarding the company's ability to continue as a 'going concern,' indicating potential doubts about its long-term viability without significant operational improvements.

The backstory

Omkar Speciality Chemicals has been undergoing a significant financial and operational restructuring under the CIRP framework. The resolution plan, approved by the NCLT, involves a total resolution amount of ₹26.65 crore, with ₹23.14 crore allocated for creditors. A capital infusion of ₹9.734 crore is also part of the plan.

Despite these measures and the official exit from insolvency, the core business has not yet resumed generating revenue. Management is preparing results on a going concern basis, banking on the resolution plan and anticipated operational revival.

What changes now

With the CIRP concluded and new management in place, the focus shifts entirely to operational revival and financial stabilization. The company is expected to implement the approved resolution plan.

The new leadership will be tasked with restarting revenue-generating activities, managing the infused capital, and addressing the concerns raised by the auditors. The constituted committees will oversee critical functions like audit and stakeholder relations.

Risks to watch

Zero Revenue: The most immediate risk is the complete absence of operating revenue, which needs urgent rectification for any meaningful recovery.

Negative Net Worth: The company continues to have a negative net worth, indicating a significant gap between its liabilities and assets.

Going Concern Uncertainty: The auditor's qualification is a major red flag, suggesting that the company's ability to continue operating in the foreseeable future is in doubt without successful operational turnaround and financial restructuring.

Peer comparison

Companies emerging from insolvency often face a challenging path to recovery. While Omkar Speciality Chemicals has completed its CIRP, many peers in the speciality chemicals sector are focused on growth and innovation, reporting positive revenues and profits. The key differentiator for OSCL is its current lack of operational revenue post-resolution.

Context metrics (time-bound)

• Net Loss (9 months ended 31.12.2025): ₹-1,25.62 lakh
• Net Loss (Quarter ended 30.09.2025): ₹-51.79 lakh
• Revenue from operations (Q ended 30.09.2025 & 31.12.2025): ₹0.00 crore
• Resolution Plan Approval Date: July 31, 2025
• Total Resolution Amount: ₹26.65 crore
• Capital Infusion: ₹9.734 crore (up to Sept 2025)

What to track next

Investors should closely monitor future quarterly results for any signs of revenue generation. The company's ability to successfully implement its revival strategy and address the auditor's concerns regarding its going concern status will be critical. Any updates on restarting core business activities will be key indicators.